*A.R. and N.W.S. contributed equally to this work
Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study
Article first published online: 13 MAR 2013
Copyright © 2013 UICC
International Journal of Cancer
Volume 133, Issue 5, pages 1204–1213, 1 September 2013
How to Cite
Stragliotto, G., Rahbar, A., Solberg, N. W., Lilja, A., Taher, C., Orrego, A., Bjurman, B., Tammik, C., Skarman, P., Peredo, I. and Söderberg-Nauclér, C. (2013), Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. Int. J. Cancer, 133: 1204–1213. doi: 10.1002/ijc.28111
Authors' disclosure of potential conflicts of interest: Over 4 years ago, CSN received speaker's fees and sponsored travel costs for presentations of her own research group's basic science data on the indirect molecular effects of HCMV at scientific meetings.
Author contributions: CSN and IP designed the study. GS and IP included and treated patients and collected the patient data. AR analyzed and performed PCR, ELISA and immunohistochemistry analyses for HCMV diagnostics, MGMT and VEGF analyses, AR and AO evaluated the immunohistochemistry grading for HCMV, and AO evaluated the pathological diagnosis. N.W.S. had main administrative responsibility and helped with handling clinical samples. BB served as research nurse and handled patient data for eCRF files. PS and CT handled clinical samples and PS had administrative responsibilities. CSN collected and interpreted the virology and immunology data. AL performed MRI analyses of tumor volumes. CSN and GS interpreted the data and drafted the report. All authors reviewed the draft, provided comments, and approved the final version of the report.
- Issue published online: 18 JUN 2013
- Article first published online: 13 MAR 2013
- Accepted manuscript online: 13 FEB 2013 02:58AM EST
- Manuscript Accepted: 28 JAN 2013
- Manuscript Received: 11 SEP 2012
- Hoffmann La Roche
- Torsten and Ragnar Söderbergs Foundation
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.